Dyne Therapeutics, Inc. (DYN)

Dyne Therapeutics, Inc. is trading at $15.50, down 1.71% on the session. The 50 day average sits at $20.53 and the 200 day at $19.41, which puts the stock in a uptrend. RSI is at 27.1, which reads as oversold, and MACD is bullish crossover. Volume is below average.

The nearest support is around $14.13 with resistance near $16.80, so that band frames the current range. Average daily movement is roughly $0.93, or about 6.0% of the share price, which is what any stop placement has to allow for. The overall health score of 42 out of 100 combines a trend score of 30, momentum of 52 and a risk score of 46.

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.